Project
CAHmelia SPR001-203
Ongoing - recruitment active · 2021 until 2025
Bilz Stefan, Krull Ina, Räss Andrea
Type
Clinical Studies
Range
Multicentric, KSSG as participating partner
Units
Status
Ongoing - recruitment active
Start Date
2021
End Date
2025
Financing
Industry
Study Design
Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study
Brief description/objective
A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia